Zogenix, Inc.
0M3O.L
London Stock Exchange40.75
USD
+14.38
- -
Zogenix, Inc.
0M3O.L
(London Stock Exchange)
Recent
price
40.75
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Zogenix, Inc. (ticker: 0M3O.L) develops and commercializes therapies for patients living with rare diseases, with a primary focus on rare epilepsies; its lead product is FINTEPLA (fenfluramine) oral solution C-IV, approved in the United States and Europe for the treatment of seizures associated with Dravet syndrome in patients two years of age and older, and under regulatory review for seizures associated with Lennox-Gastaut syndrome (LGS) and CDKL5 Deficiency Disorder (CDD); the company also advances MT-1621 for TK2 deficiency, a mitochondrial disease. Zogenix operates in the biopharmaceutical industry, targeting rare and orphan diseases in neurology, primarily serving patients, caregivers, and healthcare providers in the United States, Europe, and Japan. Founded in 2006 and formerly headquartered in Emeryville, California, Zogenix was acquired by UCB SA in March 2022 for up to approximately $1.9 billion, including $26.00 per share in cash plus a contingent value right; post-acquisition, its products integrate into UCB's neurology portfolio, enhancing epilepsy treatments and global commercialization efforts.